GlaxoSmithKline Stock Performance

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

The company retains a Market Volatility (i.e. Beta) of 0.6314, which attests that as returns on market increase, GlaxoSmithKline PLC returns are expected to increase less than the market. However, during bear market, the loss on holding GlaxoSmithKline PLC will be expected to be smaller as well. Although it is extremely important to respect GlaxoSmithKline PLC current price history, it is better to be realistic regarding the information on equity current price movements. The philosophy in determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By evaluating GlaxoSmithKline PLC technical indicators you can presently evaluate if the expected return of 0.0282% will be sustainable into the future. GlaxoSmithKline PLC right now retains a risk of 3.15%. Please check out GlaxoSmithKline PLC Coefficient Of Variation, Semi Variance, Price Action Indicator, as well as the relationship between Treynor Ratio and Daily Balance Of Power to decide if GlaxoSmithKline PLC will be following its current trending patterns.

Search Stock Performance

 
Refresh
00

GlaxoSmithKline PLC Risk-Adjusted Performance

Over the last 30 days GlaxoSmithKline PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Regardless of fairly consistent technical and fundamental indicators, GlaxoSmithKline PLC is not utilizing all of its potentials. The existing stock price confusion, may contribute to short-horizon losses for the traders.
Quick Ratio0.54
Fifty Two Week Low31.43
Target High Price51.00
Fifty Two Week High48.25
Payout Ratio74.09%
Trailing Annual Dividend Yield2.58%
Target Low Price43.75

GlaxoSmithKline PLC Relative Risk vs. Return Landscape

If you would invest  4,259  in GlaxoSmithKline PLC on May 4, 2020 and sell it today you would lose (56.00)  from holding GlaxoSmithKline PLC or give up 1.31% of portfolio value over 30 days. GlaxoSmithKline PLC is generating 0.0282% of daily returns assuming volatility of 3.1537% on return distribution over 30 days investment horizon. In other words, 27% of equities are less volatile than the company and above 99% of equities are expected to generate higher returns over the next 30 days.
 Daily Expected Return (%) 
      Risk (%) 
Considering 30-days investment horizon, GlaxoSmithKline PLC is expected to generate 2.0 times less return on investment than the market. But when comparing it to its historical volatility, the company is 1.27 times less risky than the market. It trades about 0.01 of its potential returns per unit of risk. The DOW is currently generating roughly 0.01 of returns per unit of risk over similar time horizon.

GlaxoSmithKline PLC Market Risk Analysis

Sharpe Ratio = 0.009
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsGSK

GlaxoSmithKline PLC Stock Performance Indicators

Estimated Market Risk
 3.15
  actual daily
 
 27 %
of total potential
 
2727
Expected Return
 0.03
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 0.01
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average GlaxoSmithKline PLC is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlaxoSmithKline PLC by adding it to a well-diversified portfolio.

GlaxoSmithKline PLC Alerts

Equity Alerts and Improvement Suggestions

GlaxoSmithKline PLC has very high historical volatility over the last 30 days
GlaxoSmithKline PLC has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial commitments
The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
GLAXOSMITHKLINE P has about 5.12 B in cash with (5.78 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.08.
On 14th of May 2020 GlaxoSmithKline PLC paid $ 0.472 per share dividend to its current shareholders
Latest headline from www.bloomberg.com: Glaxo to Make 1 Billion Doses of Pandemic Vaccine Booster - Bloomberg

GlaxoSmithKline PLC Dividends

GlaxoSmithKline PLC Dividends Analysis

Check GlaxoSmithKline PLC dividend payout schedule and payment analysis over time. Analyze past dividends calendar and estimate annual dividend income
Check Dividends  
Please check Risk vs Return Analysis. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page